Except for statins, there are two commonly used lipid-lowering medications that target specific factors: ezetimibe targeting Niemann-Pick C1-like 1 (NPC1L1) [18] and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [19], research on their associations with IBD are limited. This evidence concerns the gene PCSK9 and inflammatory bowel disease.